Associates in Poland
and abroad
Global
English
Global
English
Global
English
Poland
polski
Czechia
Český
Italy
Italiano
Kazakhstan
Қазақ
Slovakia
Slovenský
Spain
Español
Russia
Pусский
Ukraine
Український
Uzbekistan
Ўзбекча
Vietnam
Tiếng việt
x
About Adamed
About Adamed
We are a pharmaceutical and biotechnology company established on the basis of Polish scientific advances and our own patents.
Adamed is one of the ten largest pharmaceutical companies operating in Poland. Adamed is the leader in next-generation pharmaceuticals – we were the first Polish company to undertake research into innovative therapies back in 2001. We have invested 1.5 billion Polish zloty in research and development to date, and our portfolio currently boasts around 500 products. We establish industry-academia consortia with leading universities and research institutes in Poland and abroad.
Over 30 years of innovation and 130 years of tradition
1986
Adamed was founded by Marian Adamkiewicz MD, PhD
1991
The first drug for treatingurinary tract infections is launched. The development of an original technology for producing high-grade furaginum makes treatment for urologic conditions available to millions of patients
1994
The first manufacturing facility is opened in Pieńków, near Warsaw
1998
The first Polish-made amlodipine is registered. The method of synthesising amlodipine is improved: the new production process, that was first developed in Poland, means the number of patients who can benefit from the therapy has grown significantly, from 75,000 to more than 1.5 million today
1999-2000
The Research and Development Division is established. Adamed meets the standards of good manufacturing practice established by the European Union and is awarded the GMP EU certificate
2001
Research into innovative drugs (in the areas of oncology and central nervous system diseases) is initiated
2002
A second manufacturing plant is opened in Ksawerów, near Łódź
2003
Adamed starts exporting its products
2005-2009
The first industry-academia consortium is formed with the Jagiellonian University
2010
Acquisition of Polfa Pabianice and Agropharm
2010-2012
Adamed undergoes consolidation. Establishment of a branch in Russia
2013
Establishment of a branch in Kazakhstan
2013-2014
The construction of Adamed’s state-of-the-art R&D Centre begins
2015
The Oncotrail project is launched
2016
Adamed’s state-of-the-art R&D Centre becomes operational. The company establishes branches in Slovakia and the Czech Republic
2017
Acquisition of a controlling interest in the Vietnamese pharmaceutical company Dat Vi Phu
2018
Pilot R&D Production Area (Pilot Plant) becomes operational